NCT07080931View on ClinicalTrials.gov

Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia

PHASE3RecruitingINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

February 24, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Androgenetic Alopecia
Interventions
DRUG

5% minoxidil foam

Participants applied 5% minoxidil foam topically once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.

DRUG

Placebo for 5% Minoxidil Foam

Participants applied placebo once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.

Trial Locations (1)

Unknown

RECRUITING

Beijing, China, Beijing

All Listed Sponsors
lead

Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.

INDUSTRY